Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: lafeber m. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
Sablerolles RSG, Goorhuis A, GeurtsvanKessel CH, de Vries RD, Huckriede ALW, Koopmans MPG, Lafeber M, Postma DF, van Baarle D, Visser LG, Dalm VASH, Kootstra NA, Rietdijk WJR, van der Kuy PHM. Sablerolles RSG, et al. Among authors: lafeber m. Front Immunol. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319. eCollection 2021. Front Immunol. 2021. PMID: 34691071 Free PMC article. No abstract available.
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH; SWITCH Research Group. Sablerolles RSG, et al. Among authors: lafeber m. Clin Infect Dis. 2023 Feb 8;76(3):e533-e536. doi: 10.1093/cid/ciac495. Clin Infect Dis. 2023. PMID: 35723273 Free PMC article.
COvid MEdicaTion (COMET) study: protocol for a cohort study.
Sablerolles RSG, Hogenhuis FEF, Lafeber M, van de Loo BPA, Borgsteede SD, Boersma E, Versmissen J, van der Kuy HM; COMET Research team. Sablerolles RSG, et al. Among authors: lafeber m. Eur J Hosp Pharm. 2020 Jul;27(4):191-193. doi: 10.1136/ejhpharm-2020-002329. Eur J Hosp Pharm. 2020. PMID: 32587077 Free PMC article.
No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study.
Sablerolles RSG, Hogenhuis FEF, Lafeber M, van de Loo BPA, Borgsteede SD, Boersma E, Versmissen J, van der Kuy H; COMET Research Team. Sablerolles RSG, et al. Among authors: lafeber m. Br J Clin Pharmacol. 2021 Aug;87(8):3301-3309. doi: 10.1111/bcp.14751. Epub 2021 Feb 18. Br J Clin Pharmacol. 2021. PMID: 33507556 Free PMC article.
Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study.
Sablerolles RSG, Lafeber M, van Kempen JAL, van de Loo BPA, Boersma E, Rietdijk WJR, Polinder-Bos HA, Mooijaart SP, van der Kuy H, Versmissen J, Faes MC; COMET research team. Sablerolles RSG, et al. Among authors: lafeber m. Lancet Healthy Longev. 2021 Mar;2(3):e163-e170. doi: 10.1016/S2666-7568(21)00006-4. Epub 2021 Feb 9. Lancet Healthy Longev. 2021. PMID: 33655235 Free PMC article.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?
Versmissen J, Verdonk K, Lafeber M, van den Akker JPC, Hunfeld NGM, Hoorn EJ, Danser AHJ. Versmissen J, et al. Among authors: lafeber m. J Hypertens. 2020 Jun;38(6):1196-1197. doi: 10.1097/HJH.0000000000002472. J Hypertens. 2020. PMID: 32371817 Free PMC article. No abstract available.
37 results